Trajectories of Perioperative Serum Tumor Markers and Colorectal Cancer Outcomes: A Retrospective, Multicenter Longitudinal Cohort Study

Li, Chunxia; Zhang, Dafu; Pang, Xiaolin; Pu, Hongjiang; Lei, Ming; Fan, Bingbing; Lv, Jidong; You, Dingyun; Li, Zhenhui; Zhang, Tao

doi:10.1016/j.ebiom.2021.103706

Cited by 20 publications

(12 citation statements)

References 32 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, these results were in line with the conclusion that the expression of m 5 C signatures in CRC tissue was related to different clinical outcomes and tumor status found by other researchers (19). It might be since with the development of the stage, more tumor cells were released into the blood during epithelial-mesenchymal transition (EMT), affecting the phenotype of immune cells (27)(28)(29).…”

Section: Discussionsupporting

confidence: 88%

“…The blood tumor biomarkers CEA, CA19-9, and CA125, were broadly employed for physical screening of CRC ( 7 ). However, these three indicators were more appropriate for postoperative risk monitoring in CRC patients due to their lower sensitivity ( 30 ). Our results displayed that m 5 C modification discriminated between CRC patients and healthy recipients with an AUC of 0.888 (95% CI, 0.835-0.941), was substantially superior to that of CEA (0.739; 95% CI, 0.660-0.818), CA19-9 (0.669; 95% CI, 0.583-0.755), and CA125 (0.629; 95% CI, 0.540-0.718) for AUC in the training set ( Figure 2C ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

5-Methylcytosine (m5C) modification in peripheral blood immune cells is a novel non-invasive biomarker for colorectal cancer diagnosis

et al. 2022

View full text Add to dashboard Cite

Current non-invasive tumor biomarkers failed to accurately identify patients with colorectal cancer (CRC), delaying CRC diagnosis and thus leading to poor prognosis. Dysregulation of 5-Methylcytosine (m5C) RNA has gradually been reported in various cancers, but their role in tumor diagnosis is rarely mentioned. Our study aimed to determine the role of m5C methylation modification in blood immune cells for the diagnosis of CRC. Peripheral blood samples were obtained from a total of 83 healthy controls and 196 CRC patients. We observed that m5C RNA contents in blood immune cells of CRC patients were markedly enhanced in both training set and validation set. Moreover, levels of m5C increased with CRC progression and metastasis but reduced after treatment. Compared with common blood tumor biomarkers, m5C levels in peripheral blood immune cells had superior discrimination and reclassification performance in diagnosing CRC. Besides, bioinformatics and qRT-PCR analysis identified increased expression of m5C-modified regulators NSUN5 and YBX1 in CRC patients’ blood. A series of animal models and cell co-culture models further demonstrated that CRC tumor cells could increase immune cells’ m5C levels and m5C-modified regulators. Monocyte was the predominant m5C-modified immune cell type in CRC patients’ blood by Gene set variation analysis (GSVA). Taken together, m5C methylation modification in peripheral blood immune cells was a promising biomarker for non-invasive diagnosis of CRC.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 99%

5-Methylcytosine (m5C) modification in peripheral blood immune cells is a novel non-invasive biomarker for colorectal cancer diagnosis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…This finding is consistent with previous studies and anticipated outcomes (25,46,47). The severity of the tumor burden and inflammatory response mirrors the progression of MLBO (48)(49)(50). This congruence further supports the robustness of our predictive model and accentuates the significance of these factors in determining the prognosis of MLBO patients.…”

Section: /42supporting

confidence: 91%

Application of machine learning in the prognosis prediction of malignant large bowel obstruction: a two-cohort study

Chen,

Zhang,

et al. 2024

Preprint

View full text Add to dashboard Cite

Background The Colon and Rectal NCCN Clinical Practice Guidelines currently identify obstructions as risk factors rather than as specific types. A personalized and intelligent prognostic evaluation system for malignant large bowel obstruction (MLBO) is urgently needed. Methods We conducted a retrospective study on 170 MLBO patients who underwent radical excision at two centers. The training and validation sets were randomly derived from the combined data of each center at a 7:3 ratio. We employed machine learning methods, including the logistic regression classifier (LR), linear discriminant analysis classifier (LDA), extreme gradient boosting classifier (XGB), AdaBoost classifier (AB), and light gradient boosting machine classifier (LGBM). These classifiers were based on clinical features (clinical model), radiological features (radiomics model), and their combination (merged model). The best model was identified through the area under the operating characteristic curve (AUC). Results Using clinicopathologic parameters, clinicopathologic models XGB achieved an impressive AUC of 0.97 for DFS, and LDA maintained strong performance with an AUC of 0.92 for OS, rather than radio-omics and dual-omics models. Using the Qingdao Center(QD) dataset as a single validation set, the model performance was not ideal due to demographic differences, with AUC values of 0.42 and 0.50 for DFS and OS, respectively. Finally, when cross-training and validating clinicopathological features from two centers were conducted, LDA exhibited exceptional performance for both DFS and OS, with AUCs of 0.96 and 0.95, respectively. Regardless of DFS or OS, the worse prognosis group had higher levels of the following metrics compared to the better prognosis group. [For DFS: pT(p < 0.001), pN(p < 0.006), pM(p < 0.001), monocyte count(0.64 vs. 0.52, p = 0.038), and carbohydrate antigen 199(CA199) (27.59 vs. 15.14, p = 0. 006); For OS: pT(p = 0.002), pN(p = 0.002) and pM(p < 0.001), as well as LVI (p = 0.037), monocyte count(0.68 vs. 0.51, p = 0.005) and CA199 (31.78 vs. 15.88, p = 0.006)]. Conclusions High-efficacy models for the prognosis prediction of MLBO via clinicopathological features across two centers was constructed. We recommend heightened vigilance for MLBO patients with a high TNM stage, lymphovascular invasion occurrence, elevated CA199 levels, and high monocyte count.

show abstract

“…The commonly used methods for the diagnosis and prognosis of cancers are (1) imaging examination: including X-ray, CT, magnetic resonance imaging (MRI), ultrasound, endoscopy, glucose metabolism technology and positron emission tomography (PET), radionuclide imaging examination and other imaging methods [ 3 , 4 , 5 ]; (2) molecular marker examination: including detection of tumor markers such as carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), and various carbohydrate antigens (such as CA125 and CA19) and some tumor-related biochemical indicators such as acid phosphatase (ACP), estrogen receptor (ER), and progesterone receptor (PR) in serum urine of patients [ 4 , 6 , 7 , 8 , 9 ]; (3) pathological examination where the abnormal tissue samples are collected for pathological examination by techniques such as immunohistochemistry (IHC), HE staining, and fluorescence in situ hybridization (FISH) [ 10 , 11 ]; (4) detection of circulating tumor cells (CTC), such as detection of tumor cells in peripheral blood, which can be used to monitor and predict the prognosis of tumor metastasis [ 12 , 13 ]; (5) body fluid cytological diagnosis, including detection of tumor cells by sputum, urine and other liquids or by means of puncture [ 14 , 15 ]; and (6) other examinations: including digital rectal examination (DRE), fecal occult blood test (FOBT), and other diagnostic methods [ 16 , 17 ].…”

Section: Introductionmentioning

confidence: 99%

Overview of MicroRNAs as Diagnostic and Prognostic Biomarkers for High-Incidence Cancers in 2021

Sun

Zhao

Wang

et al. 2022

IJMS

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are small non-coding RNAs (ncRNAs) about 22 nucleotides in size, which play an important role in gene regulation and are involved in almost all major cellular physiological processes. In recent years, the abnormal expression of miRNAs has been shown to be associated with human diseases including cancer. In the past ten years, the link between miRNAs and various cancers has been extensively studied, and the abnormal expression of miRNAs has been reported in various malignant tumors, such as lung cancer, gastric cancer, colorectal cancer, liver cancer, breast cancer, and prostate cancer. Due to the high malignancy grade of these cancers, it is more necessary to develop the related diagnostic and prognostic methods. According to the study of miRNAs, many potential cancer biomarkers have been proposed for the diagnosis and prognosis of diseases, especially cancer, thus providing a new theoretical basis and perspective for cancer screening. The use of miRNAs as biomarkers for diagnosis or prognosis of cancer has the advantages of being less invasive to patients, with better accuracy and lower price. In view of the important clinical significance of miRNAs in human cancer research, this article reviewed the research status of miRNAs in the above-mentioned cancers in 2021, especially in terms of diagnosis and prognosis, and provided some new perspectives and theoretical basis for the diagnosis and treatment of cancers.

show abstract

Trajectories of Perioperative Serum Tumor Markers and Colorectal Cancer Outcomes: A Retrospective, Multicenter Longitudinal Cohort Study

Cited by 20 publications

References 32 publications

5-Methylcytosine (m5C) modification in peripheral blood immune cells is a novel non-invasive biomarker for colorectal cancer diagnosis

5-Methylcytosine (m5C) modification in peripheral blood immune cells is a novel non-invasive biomarker for colorectal cancer diagnosis

Application of machine learning in the prognosis prediction of malignant large bowel obstruction: a two-cohort study

Overview of MicroRNAs as Diagnostic and Prognostic Biomarkers for High-Incidence Cancers in 2021

Contact Info

Product

Resources

About